Home.md
... ...
@@ -24,134 +24,134 @@ config:
24 24
nodeAlignment: right
25 25
---
26 26
sankey-beta
27
-
28
-Sanger, 2001, 4
29
-2001, Pasqualucci 2001, 4
30
-Pasqualucci 2001, DLBCL Tier 1, 3
31
-Pasqualucci 2001, DLBCL Tier 2, 1
32
-
33
-RNA-seq/WGS, 2011, 49
34
-2011, Morin 2011, 25
35
-Morin 2011, DLBCL Tier 1, 25
36
-2011, Morin 2011, 15
37
-Morin 2011, FL Tier 1, 14
38
-Morin 2011, FL Tier 2, 1
39
-2011, Pasqualucci 2011a, 7
40
-Pasqualucci 2011a, DLBCL Tier 1, 5
41
-Pasqualucci 2011a, DLBCL Tier 2, 2
42
-2011, Pasqualucci 2011b, 2
43
-Pasqualucci 2011b, FL Tier 1, 2
44
-Pasqualucci 2011b, DLBCL Tier 1, 2
45
-
46
-exome, 2012 exome studies, 68
47
-2012 exome studies, Richter 2012, 5
48
-2012 exome studies, Lohr 2012, 4
49
-2012 exome studies, Love 2012, 59
50
-
51
-Richter 2012, BL Tier 1, 5
27
+Albuquerque 2017, DLBCL Tier 1, 3
52 28
Lohr 2012, DLBCL Tier 1, 3
53 29
Lohr 2012, DLBCL Tier 2, 1
54
-Love 2012, BL Tier 1, 3
55
-Love 2012, BL Tier 2, 56
56
-
57
-RNA-seq, 2012 , 19
58
-2012 , Schmitz 2012, 19
59
-Schmitz 2012, BL Tier 1, 3
60
-Schmitz 2012, BL Tier 2, 16
61
-
62
-WGS, 2013 WGS studies, 40
63
-2013 WGS studies, Morin 2013, 40
30
+Pasqualucci 2001, DLBCL Tier 1, 2
31
+Pasqualucci 2001, DLBCL Tier 2, 2
32
+Mareschal 2016, DLBCL Tier 1, 2
33
+Arthur 2018, DLBCL Tier 1, 8
34
+Arthur 2018, DLBCL Tier 2, 12
35
+Morin 2016, DLBCL Tier 1, 2
64 36
Morin 2013, DLBCL Tier 1, 11
65 37
Morin 2013, DLBCL Tier 2, 29
66
-
67
-
68
-exome, 2013 exome studies, 19
69
-2013 exome studies, Zhang 2013, 19
38
+Pasqualucci 2011, DLBCL Tier 1, 2
39
+Pararajalingam 2020, DLBCL Tier 2, 2
40
+Hubschmann 2021, DLBCL Tier 1, 3
41
+Hubschmann 2021, DLBCL Tier 2, 20
42
+Chapuy 2018, DLBCL Tier 1, 2
43
+Chapuy 2018, DLBCL Tier 2, 17
44
+Pasqualucci 2011, DLBCL Tier 1, 3
45
+Pasqualucci 2011, DLBCL Tier 2, 4
46
+Reddy 2017, DLBCL Tier 1, 7
47
+Reddy 2017, DLBCL Tier 2, 53
70 48
Zhang 2013, DLBCL Tier 1, 11
71 49
Zhang 2013, DLBCL Tier 2, 8
72
-
73
-exome, 2014 exome studies, 3
74
-2014 exome studies, Muppidi 2014, 3
75
-Muppidi 2014, BL Tier 1, 1
76
-Muppidi 2014, BL Tier 2, 2
77
-
78
-exome, 2016 exome studies, 2
79
-2016 exome studies, Mareschal 2016, 2
80
-Mareschal 2016, DLBCL Tier 1, 2
81
-
82
-WGS, 2016 WGS studies, 2
83
-2016 WGS studies, Okosun 2016, 2
84
-Okosun 2016, FL Tier 1, 2
85
-
86
-exome, 2016 exome studies, 2
87
-2016 exome studies, Morin 2016, 2
88
-Morin 2016, DLBCL Tier 1, 2
89
-
90
-exome, 2017 exome studies, 85
91
-2017 exome studies, Krysiak 2017, 22
50
+Schmitz 2018, DLBCL Tier 1, 7
51
+Schmitz 2018, DLBCL Tier 2, 9
52
+Morin 2011, DLBCL Tier 1, 24
53
+Morin 2011, DLBCL Tier 2, 1
54
+DLBCL, DLBCL-exome, 7
55
+DLBCL-exome, Pasqualucci 2011, 7
56
+DLBCL, DLBCL-exome, 19
57
+DLBCL-exome, Chapuy 2018, 19
58
+DLBCL, DLBCL-WGS, 23
59
+DLBCL-WGS, Hubschmann 2021, 23
60
+DLBCL, DLBCL-WGS/exome, 2
61
+DLBCL-WGS/exome, Pararajalingam 2020, 2
62
+DLBCL, DLBCL-exome, 2
63
+DLBCL-exome, Pasqualucci 2011, 2
64
+DLBCL, DLBCL-RNA-seq/WGS, 25
65
+DLBCL-RNA-seq/WGS, Morin 2011, 25
66
+DLBCL, DLBCL-exome, 19
67
+DLBCL-exome, Zhang 2013, 19
68
+DLBCL, DLBCL-exome, 16
69
+DLBCL-exome, Schmitz 2018, 16
70
+DLBCL, DLBCL-exome, 60
71
+DLBCL-exome, Reddy 2017, 60
72
+DLBCL, DLBCL-exome, 4
73
+DLBCL-exome, Lohr 2012, 4
74
+DLBCL, DLBCL-exome, 3
75
+DLBCL-exome, Albuquerque 2017, 3
76
+DLBCL, DLBCL-exome, 2
77
+DLBCL-exome, Morin 2016, 2
78
+DLBCL, DLBCL-WGS, 40
79
+DLBCL-WGS, Morin 2013, 40
80
+DLBCL, DLBCL-exome, 2
81
+DLBCL-exome, Mareschal 2016, 2
82
+DLBCL, DLBCL-WGS, 20
83
+DLBCL-WGS, Arthur 2018, 20
84
+DLBCL, DLBCL-Sanger, 4
85
+DLBCL-Sanger, Pasqualucci 2001, 4
86
+Pasqualucci 2011, FL Tier 1, 2
87
+Hubschmann 2021, FL Tier 1, 2
88
+Hubschmann 2021, FL Tier 2, 15
92 89
Krysiak 2017, FL Tier 1, 17
93 90
Krysiak 2017, FL Tier 2, 5
94
-
95
-
96
-2017 exome studies, Albuquerque 2017, 3
97
-Albuquerque 2017, DLBCL Tier 1, 3
98
-
99
-2017 exome studies, Reddy 2017, 60
100
-Reddy 2017, DLBCL Tier 2, 50
101
-Reddy 2017, DLBCL Tier 1, 10
102
-
103
-exome, 2018 exome studies, 35
104
-2018 exome studies, Schmitz 2018, 16
105
-Schmitz 2018, DLBCL Tier 2, 7
106
-Schmitz 2018, DLBCL Tier 1, 9
107
-
108
-2018 exome studies, Chapuy 2018, 19
109
-Chapuy 2018, DLBCL Tier 2, 16
110
-Chapuy 2018, DLBCL Tier 1, 3
111
-
112
-WGS, 2018 WGS studies, 20
113
-2018 WGS studies, Arthur 2018, 20
114
-Arthur 2018, DLBCL Tier 2, 12
115
-Arthur 2018, DLBCL Tier 1, 8
116
-
117
-RNA-seq/exome,2019 ,47
118
-2019 , Panea 2019, 47
119
-Panea 2019, BL Tier 2, 43
91
+Morin 2011, FL Tier 1, 14
92
+Morin 2011, FL Tier 2, 1
93
+Okosun 2016, FL Tier 1, 2
94
+Russler-germain 2023, FL Tier 1, 1
95
+Russler-germain 2023, FL Tier 2, 19
96
+FL, FL-WGS, 17
97
+FL-WGS, Hubschmann 2021, 17
98
+FL, FL-exome, 2
99
+FL-exome, Pasqualucci 2011, 2
100
+FL, FL-RNA-seq/WGS, 15
101
+FL-RNA-seq/WGS, Morin 2011, 15
102
+FL, FL-exome, 22
103
+FL-exome, Krysiak 2017, 22
104
+FL, FL-exome, 20
105
+FL-exome, Russler-germain 2023, 20
106
+FL, FL-WGS, 2
107
+FL-WGS, Okosun 2016, 2
108
+Muppidi 2014, BL Tier 1, 1
109
+Muppidi 2014, BL Tier 2, 2
120 110
Panea 2019, BL Tier 1, 4
121
-
122
-WGS,2019 WGS studies,13
123
-2019 WGS studies, Grande 2019, 13
124
-Grande 2019, BL Tier 1, 8
125
-Grande 2019, BL Tier 2, 5
126
-
127
-exome, 2020 exome studies, 2
128
-2020 exome studies, Pararajalingam 2020, 2
129
-Pararajalingam 2020, DLBCL Tier 1, 2
130
-
131
-WGS, 2021 WGS studies, 40
132
-2021 WGS studies, Hubschmann 2021, 17
133
-2021 WGS studies, Hubschmann 2021, 23
134
-Hubschmann 2021, FL Tier 2, 15
135
-Hubschmann 2021, FL Tier 1, 2
136
-Hubschmann 2021, DLBCL Tier 1, 4
137
-Hubschmann 2021, DLBCL Tier 2, 19
138
-
139
-exome, 2023 exome studies, 20
140
-2023 exome studies, Russler-Germain 2023, 20
141
-Russler-Germain 2023, FL Tier 1, 1
142
-Russler-Germain 2023, FL Tier 2, 19
143
-
144
-Panel, panel studies, 25
145
-panel studies, Burkhardt 2022, 25
146
-Burkhardt 2022, BL Tier 2, 25
147
-
148
-WGS, 2023 WGS studies, 3
149
-2023 WGS studies, Thomas 2023, 3
150
-Thomas 2023, BL Tier 2, 1
111
+Panea 2019, BL Tier 2, 46
151 112
Thomas 2023, BL Tier 1, 2
152
-
113
+Thomas 2023, BL Tier 2, 3
114
+Grande 2019, BL Tier 1, 9
115
+Grande 2019, BL Tier 2, 4
116
+Richter 2012, BL Tier 1, 5
117
+Burkhardt 2022, BL Tier 2, 25
118
+Schmitz 2012, BL Tier 1, 3
119
+Schmitz 2012, BL Tier 2, 16
120
+Love 2012, BL Tier 1, 3
121
+Love 2012, BL Tier 2, 56
122
+BL, BL-RNA-seq/exome, 50
123
+BL-RNA-seq/exome, Panea 2019, 50
124
+BL, BL-Sanger, 3
125
+BL-Sanger, Muppidi 2014, 3
126
+BL, BL-WGS, 5
127
+BL-WGS, Thomas 2023, 5
128
+BL, BL-panel, 25
129
+BL-panel, Burkhardt 2022, 25
130
+BL, BL-WGS, 13
131
+BL-WGS, Grande 2019, 13
132
+BL, BL-RNA-seq/WGS/exome, 5
133
+BL-RNA-seq/WGS/exome, Richter 2012, 5
134
+BL, BL-exome, 59
135
+BL-exome, Love 2012, 59
136
+BL, BL-RNA-seq, 19
137
+BL-RNA-seq, Schmitz 2012, 19
138
+Zhang 2014, MCL Tier 1, 2
139
+Zhang 2014, MCL Tier 2, 26
140
+Bea 2013, MCL Tier 1, 11
141
+Bea 2013, MCL Tier 2, 16
142
+Nadeu 2020, MCL Tier 1, 3
143
+Nadeu 2020, MCL Tier 2, 2
144
+Pararajalingam 2020, MCL Tier 1, 6
145
+Pararajalingam 2020, MCL Tier 2, 1
146
+MCL, MCL-WGS/exome, 27
147
+MCL-WGS/exome, Bea 2013, 27
148
+MCL, MCL-WGS/exome, 7
149
+MCL-WGS/exome, Pararajalingam 2020, 7
150
+MCL, MCL-WGS, 5
151
+MCL-WGS, Nadeu 2020, 5
152
+MCL, MCL-exome, 28
153
+MCL-exome, Zhang 2014, 28
153 154
```
154
-
155 155
## B-cell Lymphoma aSHM targets
156 156
[hg19 coordinates](ashm)
157 157